Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Cervical Dystonia at least 9 months since onset and either previously untreated with botulinum toxin or currently treated with Botox at a total dosing range of 100-200 U and ≤60 U in the sternocleidomastoid muscle at the last injection cycle, and having had a satisfactory treatment response in the principal investigator's judgment during the last two sequential Botox treatment cycles.~* TWSTRS total score≥ 20; TWSTRS-severity subscale score\> 10;~Exclusion Criteria:~* In apparent remission from Cervical Dystonia~* Diagnosis of pure retrocollis or pure anterocollis~* For non-naïve subjects, previous poor response to either of the last two Botox treatments~* Known requirement of \<100U or \>200U of Botox injected into the neck muscles

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport® (Type: ACTIVE_COMPARATOR): Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, up to 2mL

Based on this trial design, predict the completion outcome and termination type (if applicable).